Bifidobacterium Breve Probiotic Composition for GLP-1 and Fat Metabolism

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is an urgent need for effective health management solutions to address overweight, high blood glucose, and high blood lipids, which are risk factors for cardiovascular disease, through the use of probiotics that can regulate appetite, blood glucose, and fat metabolism.

Innovation Solution

A novel strain of Bifidobacterium breve (BCRC 911145) is used to develop probiotic compositions that promote glucagon-like peptide-1 (GLP-1) secretion, inhibit adipocyte maturation, reduce fat accumulation, and modulate blood lipids and glucose levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional probiotics are used, then gastrointestinal flora can be altered, but they cannot effectively regulate appetite, blood glucose, and fat metabolism for cardiovascular disease prevention

Engineering Contradiction:

Improvehealth management effectivenessVSAvoidmulti-parameter regulation capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent identifies specific functional parameters (appetite regulation, blood glucose modulation, fat metabolism) and selects or constructs probiotic strains that can simultaneously influence these parameters. This involves changing the functional parameters of the probiotic composition to achieve multi-target health management for cardiovascular disease prevention.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If probiotics are used to regulate appetite and blood glucose, then cardiovascular disease risk factors can be reduced, but existing probiotics lack sufficient evidence for effective weight control and lipid modulation

Engineering Contradiction:

Improvecardiovascular disease preventionVSAvoidclinical evidence amount

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent introduces GLP-1 (glucagon-like peptide-1) as a key intermediary substance that mediates between probiotic consumption and multiple health benefits. GLP-1 serves as the active mediator that connects appetite regulation, blood glucose control, and weight management, providing a molecular mechanism that strengthens the evidence base for probiotic efficacy.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Adaptability or versatility

If a novel Bifidobacterium breve strain is used, then multiple health benefits can be achieved, but strain identification and validation require rigorous scientific procedures

Engineering Contradiction:

Improvemulti-functionalityVSAvoidstrain validation process

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent replaces complex mechanical strain validation procedures with molecular biological methods, specifically whole-genome sequencing and bioinformatics analysis. This substitution allows for rapid and accurate identification of the novel Bifidobacterium breve strain (BCRC 911145), confirming its taxonomic status and functional potential without requiring lengthy traditional characterization processes.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The Bifidobacterium breve strain effectively reduces appetite, enhances GLP-1 secretion, inhibits adipocyte maturation, promotes fat metabolism, and modulates blood lipids and glucose levels, demonstrating significant improvements in weight management and lipid profiles in both in vitro and human trials.

Implementation Method 1

Probiotics are defined as active microorganisms that are present in sufficient amounts to alter the gastrointestinal flora of the host and produce beneficial health effects

Methodology Applied

Scientific EffectMicrobial metabolism: Fermentation

Implementation Method 2

Probiotics can usually cause a decrease in intestinal pH by lactic acid stimulation, which in turn produces products that contribute to the growth of more beneficial microorganisms

Methodology Applied

Scientific EffectLactic acid production: Fermentation

Data Source

PatentUS20250213628A1Bifidobacterium breve, composition comprising bifidobacterium breve or culture thereof, and use of bifidobacterium breve or culture thereof

Publication Date: 2025.07.03 TCI CO LTD(CN)

AI summary

Provided are Bifidobacterium breve and a probiotic composition comprising the strain. Bifidobacterium breve was deposited in the Bioresource Collection and Research Center of Food Industry Research and Development Institute Taiwan, China on Aug. 8, 2022, and the deposit number BCRC 911145 was obtained. Further provided is use of the strain or a culture thereof in the preparation of a composition for inhibiting maturation of adipocytes, a composition for reducing fat accumulation and/or promoting fat metabolism, a composition for reducing weight, a composition for regulating blood esters, or a composition for regulating blood glucose.